Gingyo Gedokusan vs Oseltamivir for the Treatment of Uncomplicated Influenza and Influenza-like illness : An Open-label Prospective Study
-
- Iwata Kentaro
- Division of Infectious Diseases Therapeutics, Kobe University Graduate School of Medicine
-
- Igarashi Wataru
- Division of Infectious Diseases Therapeutics, Kobe University Graduate School of Medicine
-
- Honjo Midori
- Medical Research Division. Accerise Inc.
-
- Nishimoto Takashi
- Nishimoto Clinic
-
- Shinya Kyoko
- Division of Zoonosis, Kobe University Graduate School of Medicine
-
- Makino Akiko
- Division of Zoonosis, Kobe University Graduate School of Medicine
-
- Mitani Kazuo
- Mitani Family Clinic
-
- Tatsumi Yoshiko
- Mitani Family Clinic
-
- Ninomiya Hiroyuki
- Ninomiya Medical Clinic
-
- Higasa Kumi
- Kawasaki Clinic
-
- Usuki Seiichiro
- Usuki Cardiovascular Clinic
-
- Kagawa Hiroki
- Division of Infectious Diseases
-
- Uchida Daisuke
- Department of Nephrology and Hypertension, St. Marianna University School of Medicine
-
- Takimoto Kohei
- Department of Anesthesiology and Intensive Care, Osaka University School of Medicine
-
- Suganaga Rei
- Kameda Family Clinic Tateyama
-
- Matsuo Hiroo
- Division of Infectious Diseases Therapeutics, Kobe University Graduate School of Medicine
-
- Oba Yuichiro
- Department of General Medicine, Osaka General Medical Center
-
- Horigome Mami
- Division of Infectious Diseases Therapeutics, Kobe University Graduate School of Medicine
-
- Oka Hideaki
- Department of General Internal Medicine, Kanto Rosai Hospital
-
- Ohji Goh
- Division of Infectious Diseases Therapeutics, Kobe University Graduate School of Medicine
-
- Abe Yasuhisa
- Department of Medicine, Yodogawa Christian Hospital
-
- Yoshida Hiroyuki
- Department of Infection Control, Kobe University Hospital
-
- Kinoshita Shohiro
- Department of Laboratory Medicine, Kobe University Hospital
-
- Hirai Midori
- Department of Pharmacy, Kobe University Hospital
この論文をさがす
抄録
Background: Gingyo-gedoku-san (GGGS) is an herbal medicine approved for upper respiratory infections in Japan. We conducted an open-label, multi-center, prospective trial, comparing GGGS with oseltamivir in patients with influenza and influenza-like illness (ILI) as a pilot study.<br>Methods: Subjects were healthy persons aged between 16 and 40, and were enrolled from January 12, 2010 to March 24, 2011. Fifteen patients were enrolled in this trial (8 and 7 for GGGS and oseltamivir, respectively). RT-PCR was positive for pandemic influenza A (H1N1) in 10 patients. The patients were provided with either GGGS or oseltamivir for 5 days. The primary outcome was mortality and/or hospitalization 7 days after the initial diagnosis. Body temperature and other clinical characteristics were also evaluated.<br>Results: All patients recovered from illness without complication or hospitalization. The mean time to resolve symptoms for the GGGS and oseltamivir groups was 3.9 days and 3.3 days, respectively (p=0.43). The GGGS group appeared to have a smaller symptom score AUC than the oseltamivir group, (p=0.26). Time to recover activity level appeared to be shorter in the GGGS group (p=0.10), with shorter time to recover health status (p=0.02). Sub-group analysis on patients with positive PCR showed similar results between the two groups.<br>Conclusion: GGGS was associated with symptom improvements resembling oseltamivir for both influenza and ILI. Randomized controlled trials involving larger sample sizes are needed to confirm these results.
収録刊行物
-
- General Medicine
-
General Medicine 14 (1), 13-22, 2013
一般社団法人 日本プライマリ・ケア連合学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390282680166392064
-
- NII論文ID
- 130003373142
-
- ISSN
- 18836011
- 13460072
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可